

1 **Novel mutation leading to splice donor loss in a conserved site of *DMD***
2 **causes cryptorchidism**

3 Jianhai Chen^{1,2,#}, Yangying Jia^{1,2}, Jie Zhong¹, Kun Zhang³, Hongzheng Dai⁴,
4 Guanglin He⁵, Fuping Li^{6,#}, Li Zeng^{7,#}, Chuanzhu Fan^{8,#}, Huayan Xu^{3,#}

5 ¹Department of Ecology and Evolution, The University of Chicago, 1101E 57th
6 Street, Chicago, Illinois 60637, USA

7 ²Institutes for Systems Genetics, Frontiers Science Center for Disease-related
8 Molecular Network, West China Hospital, Sichuan University, Chengdu
9 610041, P.R. China

10 ³Department of Radiology, Key Laboratory of Birth Defects and Related
11 Diseases of Women and Children of Ministry of Education, West China
12 Second University Hospital, Sichuan University, Chengdu 610041, P.R. China

13 ⁴Department of Molecular and Human Genetics, Baylor College of Medicine,
14 Houston, Texas 77030, USA

15 ⁵Institute of Rare Diseases, West China Hospital of Sichuan University,
16 Sichuan University, Chengdu, 610044 China

17 ⁶Laboratory of Molecular Translational Medicine, Center for Translational
18 Medicine, Key Laboratory of Birth Defects and Related Diseases of Women
19 and Children (Sichuan University), Ministry of Education, Clinical Research
20 Center for Birth Defects of Sichuan Province, West China Second University
21 Hospital, Sichuan University, Chengdu, 610041, P.R. China

22 ⁷The Department of Pediatric Surgery, West China Hospital, Sichuan
23 University, Chengdu 610041, China

24 ⁸Department of Biological Sciences, Wayne State University, Detroit, Michigan,
25 48202, USA

26 #Corresponding author: jianhaichen@uchicago.edu; xuhuayan89@sina.com;
27 zengli998@163.com; ex3922@wayne.edu; lfpSnake@scu.edu.cn

28

29 **Abstract**

30 **Background** As one of the most common congenital abnormalities in male
31 births, cryptorchidism has been found to have a polygenic etiology according
32 to previous studies of common variants. However, little is known about
33 genetic predisposition of rare variants for cryptorchidism, since rare variants
34 have larger effective size on diseases than common variants.

35 **Methods** In this study, a cohort of 115 Chinese probands with cryptorchidism
36 was analyzed using whole-genome sequencing (WGS), alongside 19 parental
37 controls and 2136 unaffected men. Additionally, CRISPR-Cas9 editing of a
38 conserved variant was performed in a mouse model, with MRI screening
39 utilized to observe the phenotype.

40 **Results** In 30 of 115 patients (26.1%), we identified four novel genes (*ARSH*,
41 *DMD*, *MAGEA4*, and *SHROOM2*) affecting at least five unrelated patients and
42 four known genes (*USP9Y*, *UBA1*, *BCORL1*, and *KDM6A*) with the candidate
43 rare pathogenic variants affecting at least two cases. Burden tests of rare
44 variants revealed the genome-wide significances for newly identified genes (p
45 $< 2.5 \times 10^{-6}$) under the Bonferroni correction. Surprisingly, novel and known
46 genes were mainly from X chromosome (seven on X and one on Y) and all
47 rare X-chromosomal segregating variants exhibited a maternal inheritance
48 rather than *de novo* origin. CRISPR-Cas9 mouse modeling of a splice donor
49 loss variant in *DMD* (NC_000023.11:g.32454661C>G), which resides in a
50 conserved site across vertebrates, replicated bilateral cryptorchidism
51 phenotypes, confirmed by Magnetic resonance imaging (MRI) at 4 and 10
52 weeks.

53 **Conclusion** Our results revealed the role of the *DMD* gene mutation in
54 causing cryptorchidism. The results also suggest that maternal-X inheritance
55 of pathogenic defects could have a predominant role in the development of
56 cryptorchidism.

57 **Keywords:** molecular diagnosis; WGS; rare variants; male-specific disease;
58 male hemizygosity

59 **Introduction**

60 Cryptorchidism (also known as 'hidden testicle', OMIM 219050) has a global
61 prevalence rate of 2% to 4% at full-term birth in boys ¹. Despite its relatively
62 low prevalence, cryptorchidism is the most common birth defect involving
63 urogenital abnormalities in newborn boys. It is also the best-characterized risk
64 factor for infertility and testicular cancer ². Normally, the testes spontaneously
65 descend into the scrotum by the eighth month (33 weeks) of pregnancy, likely
66 triggered by transient activation of the hypothalamus-pituitary-gonadal (HPG)
67 axis, leading to an increase in reproductive hormone levels ^{3,4}. In patients with
68 cryptorchidism, one or both testes may fail to descend completely into the
69 dependent part of the scrotum, resulting in unilateral or bilateral
70 cryptorchidism, respectively.

71 Maternal risk factors before and during pregnancy, such as maternal smoking,
72 endocrine-disrupting chemicals, and gestational diabetes, have increasingly
73 been recognized as the risk factors for congenital cryptorchidism ⁵. However,
74 the studies on genetic risk factors of cryptorchidism are still limited. Multiple
75 etiological features, such as familial aggregation and increased prevalence in

76 first-degree relatives, suggest a genetic predisposition to this disease ⁶. For
77 instance, a family history of cryptorchidism can increase the risk of the
78 condition in newborn boys by approximately threefold ^{7,8}. The recurrence risk
79 has been found to be more than twice as high in brothers of cryptorchidism
80 cases compared to healthy controls ⁹. Thus, despite cryptorchidism's complex
81 susceptibility to maternal and environmental factors, strong genetic
82 components may also contribute to its etiology.

83 Previous microarray studies based on common variants (GWAS) have
84 suggested a potential association of certain pathways with cryptorchidism but
85 failed to identify specific genes, likely due to the small effect size of common
86 variants ¹⁰. Indeed, both population genetics theory and empirical data
87 suggest that rare variants have much larger effect sizes than common
88 variants ¹¹⁻¹⁴, indicating their significant role in causing genetic diseases. It is
89 estimated that most human rare protein-altering variants (missense) are
90 pathogenic ¹⁵. Furthermore, disruptive mutations (nonsense) are
91 disproportionately common causal factors in about 11.5% of human genetic
92 diseases ¹⁶. At the population level, these causal variants are rare in allele
93 frequency due to strong purifying selection, which limits their accumulation
94 across generations. Therefore, rare deleterious variants with large genetic
95 effect sizes represent a promising area for discovering causative genes for
96 genetic diseases ¹⁷, especially for diseases affecting fertility, such as
97 cryptorchidism.

98 The application of various genetic screening techniques, including whole-
99 genome and exome sequencing (WGS/WES), has facilitated the precise

100 diagnosis of numerous genetic diseases caused by rare variants¹⁸⁻²⁵. For
101 instance, a WES study on an Indian family identified a rare deleterious
102 homozygous missense variant in the *RXFP2* gene, which causes
103 cryptorchidism²⁶. Although WES is more commonly used than WGS due to its
104 lower cost, WGS offers a more uniform distribution of sequencing quality
105 (including single-nucleotide variants, insertions, and deletions) and a higher
106 discovery rate of coding-region variants, approximately 3%^{27 28}.

107 To date, a rare variants study of cryptorchidism based on WGS is still lacking.
108 In this study, we conducted rare variants screening based on WGS data for
109 134 Han Chinese samples including cases (115) and family controls (19). We
110 also used a local cohort of 2136 unaffected men for comparison. We identified
111 candidate rare pathogenic variants based on autosomal recessive, compound
112 heterozygous, and X-linked recessive inheritance mode for cryptorchidism
113 patients. We annotated these variants and recognized both known and novel
114 candidate genes and variants. We also confirmed the role of a novel rare
115 mutation in *DMD* (NC_000023.11:g.32454661C>G) in causing cryptorchidism
116 based on transgenic mouse modeling. Our study may facilitate the
117 development of molecular diagnosis and precision medicine for patients
118 suffering from cryptorchidism.

119 **Results**

120 **The MRI on typical bilateral and unilateral cryptorchidism and basic**
121 **sequencing statistics.**

122 The diagnosis of cryptorchidism was based on a physical exam by
123 professional pediatric urologists following standard protocols ²⁹. Typical
124 bilateral cryptorchidism and unilateral cryptorchidism of two patients were
125 shown using the magnetic resonance imaging (MRI) (Figure 1a-1d). In
126 comparison to controls, the patient with bilateral cryptorchidism had two non-
127 descended testes, while the patient with unilateral cryptorchidism had only
128 one undescended testis (Figure 1).

129 We conducted WGS on 115 cases and 19 family controls. Among the cases,
130 there were 21 (18.26%) bilateral cryptorchidism patients and 94 (81.74%)
131 unilateral cryptorchidism patients. This dataset also includes three family trios
132 of bilateral cryptorchidism, four trios of unilateral cryptorchidism, and three
133 duos with only cryptorchidism cases and mothers. Based on previous
134 sensitivity tests, 15x WGS depth/fold can achieve accurate SNV calling, while
135 30x is sufficient for calling indels ^{30 31}. In this study, the average sequencing
136 depths were 33.03-fold for cases and 27.97-fold for controls, suggesting a
137 balanced design of sequencing depth and quality for all samples
138 (Supplementary Table 1, Figure 1f and Supplementary Figure 1a). To confirm
139 the reported relationship, we used whole-genome SNPs to estimate the
140 relatedness between family members. We also confirmed the population
141 ancestry of all samples based on the principal component analysis (PCA).
142 Based on identity by state (IBS) distances among family members, we
143 confirmed that family members are genetically closer than unrelated
144 individuals (Supplementary Figure 1b). We also confirmed that all parents-son
145 relationships are within the coefficient range of first-degree relatives (from
146 0.177 to 0.354). By incorporating individuals from the “1000 genomes” project,

147 we further revealed that all newly sequenced samples are closely related to
148 the East Asian population (Supplementary Figure 1c).

149 **The Rare Candidate Pathogenic Variants for Known Genes**

150 With the keywords ‘cryptorchidism variants’ and ‘cryptorchidism genetics’, we
151 conducted the initial screening for known genes in the PubMed literature
152 database³². We retrieved 56 genes previously reported to be associated with
153 cryptorchidism (Supplementary Table 2). Most of these previous studies were
154 based on the genetic screening of small patient samples. Thus, it is
155 interesting to know whether these genes can be confirmed in our cohort. We
156 found that 41 of these genes were also registered in the Online Mendelian
157 Inheritance in Man (OMIM) and Human Phenotype Ontology (HPO) database
158 (June-2022) as genes related to cryptorchidism. We also added 738 genes
159 associated with cryptorchidism phenotypes from these databases. These 779
160 genes (738+41) were used as a “pool” of known genes (Supplementary Table
161 2). We annotated non-redundant variants using the online tool VEP in the
162 Ensembl database³³ and then summarized both known and novel candidate
163 genes.

164 We detected four known genes (*BCORL1*, *KDM6A*, *UBA1*, and *USP9Y*) with
165 candidate rare pathogenic variants present in at least two cases but absent in
166 paternal controls (Table 1 and Supplementary Table 3). Six variants were not

167 detected in all publicly available population databases (gnomAD, 1000
168 genomes, dbSNP, ExAC, ClinVar, etc.). One variant, *BCORL1*
169 (NC_000023.11:g.130028727G>A;NP_001171701.1:p.(G1391R)), was also
170 classified as rare based on the allele frequency of all human populations, with
171 the highest frequency in East Asian population (0.005439; Supplementary
172 Table 3). Although this allele frequency is relatively higher in the East Asian
173 population than globally, it remains much lower than the global prevalence
174 rate of cryptorchidism in boys, which is 2%-4%.

175 Interestingly, all known genes affecting at least two cases are on sex
176 chromosomes. Not a single autosomal gene was associated with more than
177 one case. This strongly suggests a predominant role of sex chromosomal
178 genes in cryptorchidism pathogenicity. The Y-chromosome gene *USP9Y*
179 (Ubiquitin Specific Peptidase 9 Y-Linked) was detected in six boys with
180 unilateral cryptorchidism. In addition, three X-chromosome genes (*BCORL1*,
181 *UBA1*, and *KDM6A*) were found to carry candidate rare pathogenic variants
182 affecting at least two patients. Strikingly, the two rare pathogenic variants in
183 *BCORL1* (NC_000023.11:g.130028727G>A; NP_001171701.1:p.(G1391R))
184 and *USP9Y* (NC_000024.10:g.12739592C>G; NP_004645.2:p.(S462C)) were
185 found in four unilateral patients per variant, with only the former registered in
186 the gnomAD database. Both variants were predicted to be deleterious by
187 multiple *in silico* algorithms (Supplementary Table 3). In addition, the wild-type

188 alleles of these variants showed evolutionary conservation in primate species,
189 based on sequence alignments of primate orthologous genes from the
190 Ensembl database (v105, Supplementary Figure 2). Together, the candidate
191 rare pathogenic variants of known genes were found to affect 12 cases,
192 indicating a molecular diagnostic rate of 10.4% (12/115). The diagnostic rates
193 for bilateral and unilateral cryptorchidism were 0% (0/21) and 12.77% (12/94),
194 respectively. These candidate pathogenic variants and genotypes in cases
195 and parents were validated using the Sanger Sequencing (Supplementary
196 Figure 3).

197 **The Rare Candidate Pathogenic Variants for Novel Genes**

198 To identify candidate pathogenic variants in novel candidate genes for
199 cryptorchidism, we excluded cases with the above-mentioned pathogenic
200 variants in known genes. Subsequently, we ranked genes based on the
201 burden of rare deleterious variants that occurred in cases. To increase the
202 reliability of the newly identified genes, we focused on genes affecting at least
203 five cases with candidate variants. We found four genes that fulfilled these
204 rigorous requirements: *DMD*, *ARSH*, *MAGEA4*, and *SHROOM2* (Table 2).

205 Based on allele frequencies in multiple genome databases (gnomAD, 1000
206 genomes, dbSNP, ExAC, ClinVar, etc.) and *in silico* predictions, all variants
207 were classified as 'rare' based on allele frequencies in normal populations

208 (allele frequency < 0.01) and classified as 'deleterious' by at least one
209 prediction method. The candidate pathogenic variants of these novel genes
210 were found in 20 cases but not in paternal controls, nor in a local cohort of
211 2136 healthy men (Supplementary Table 4). Moreover, the wild-type alleles
212 showed a primate-wide evolutionary conservation based on the Ensembl
213 sequence alignments of orthologous genes (Supplementary Figure 4).
214 Interestingly, a splice donor variant in *DMD* (NC_000023.11:g.32454661C>G)
215 is located in a site highly conserved across vertebrates, ranging from
216 mammals to birds, reptiles, and fish (Figure 3). The cases U27 and U55 both
217 had two candidate variants. Among the affected cases, four were bilateral and
218 involved in genes *ARSH*, *DMD*, and *SHROOM2*. The remaining 16 unilateral
219 cases were affected by all four genes. Thus, the diagnostic rates for bilateral
220 and unilateral cryptorchidism are 19.05% (4/21) and 17.02% (16/94),
221 respectively. Together with the known genes, the overall diagnostic rates are
222 23.81% (5/21) and 28.72% (27/94) for bilateral and unilateral cryptorchidism,
223 respectively.

224 Based on gnomAD records, five variants showed low allele frequencies in
225 both the global and East Asian population, while the remaining ten variants
226 were newly discovered without information on allele frequency in databases
227 (Supplementary Table 4). We also found recurrent variants in multiple cases:
228 NC_000023.11:g.32346044G>C; NP_000100.2:p.(Q1821E) (*DMD*, two

229 patients), NC_000023.11:g.3033050C>G; NP_001011719.1:p.(P452A)
230 (*ARSH*, three patients), NC_000023.11:g.151924064G>A;
231 NP_001011550.1:p.(A134T) (*MAGEA4*, four patients), and
232 NC_000023.11:g.9937537G>T; NP_001307593.1:p.(A166S) (*SHROOM2*, two
233 patients). These candidate variants and genotypes were also validated using
234 the Sanger Sequencing for all samples (Supplementary Figure 5).

235 **Burden Tests Support the Statistical Significance of Novel Candidate** 236 **genes**

237 To statistically test our newly identified candidate genes, we performed
238 burden tests for rare variants with the RVTEST package³⁴. We further used
239 Bonferroni correction to account for multiple testing ($p = 2.5 \times 10^{-6}$). We found
240 that five tests supported the whole-genome significance of three genes *DMD*,
241 *MAGEA4*, and *SHROOM2* (Table 3, $p < 2.5 \times 10^{-6}$). For *ARSH*, four methods,
242 except for the CMC Wald test, supported the genome-wide significance after
243 Bonferroni correction ($p < 2.5 \times 10^{-6}$).

244 **The Maternal Origin of Candidate Variants of X-chromosome Genes**

245 We identified 20 candidate X-chromosomal variants from known and novel
246 genes affecting at least two cases, based on variant screening results
247 (Supplementary Tables 3 and 4). There are two possibilities for the origin of
248 these variants: *de novo* mutation during the early embryonic development of
249 probands or during maternal oogenesis and the maternal X inheritance. For
250 the *de novo* mutation hypothesis, we would not expect to find the variant in

251 maternal genotypes. For the maternal X inheritance mode, we would detect
252 heterozygotes in maternal samples.

253 In the seven trios with WGS data, the candidate variant
254 NC_000023.11:g.151924064G>A; NP_001011550.1:p.(A134T) in *MAGEA4*
255 was detected only in proband U8 (Supplementary Table 4). The Sanger
256 Sequencing of these variants in trios indicated a maternal X-chromosome
257 origin (Figure 2a). For the duo of U9 and 9M samples, we also observed
258 maternal heterozygotes in the X-chromosomal variant genotype, despite the
259 unavailability of the paternal sample. For the additional trios with WGS-only
260 probands, the Sanger Sequencing of parental samples confirmed the
261 maternal X inheritance, in which X hemizygotes, maternal heterozygotes, and
262 paternal wild types were found simultaneously in all trios (Figure 2). Together,
263 the Sanger Sequencing of four variants, which affected seven cases and
264 parents, supported the maternal X-chromosome origin exclusively, rather than
265 *de novo* mutation from probands' embryogenesis or maternal germline. Future
266 studies based on more pedigree data are needed to further evaluate the
267 probability of *de novo* mutation during oogenesis of maternal germline or early
268 development of probands.

269 **No Reliable Compound Heterozygous Rare Variants Were Detected**

270 For compound heterozygous mode in autosomes, the family-based structure
271 can facilitate tracing of the parental origin for each rare variant. We firstly
272 focused on two heterozygous rare variants with disruptive effects on proteins
273 for patients of the seven complete trio families. Then, we relaxed the criteria

274 of variant impacts to cover the scenario of one heterozygous rare variant with
275 disruptive effect and the other with moderate impact (sequence-altering). We
276 did not find any gene fulfilling the requirements. Finally, we focused on the
277 scenario of potential compound heterozygous mode, in which non-pedigree
278 probands would carry at least two heterozygous rare variants in a gene with
279 disruptive effects. We observed two heterozygous rare variants of *RPTN* with
280 stop-gain and frameshift impacts in four unrelated patients (Supplementary
281 Table 5). However, the two variants had the same allele frequency in all
282 super-populations in the gnomAD database, suggesting that they are more
283 likely to be inherited via the linkage disequilibrium, rather than the real
284 compound heterozygous variants.

285 **CRISPR-Cas9 mouse modeling of the splice donor variant in *DMD***
286 **(NC_000023.11:g.32454661C>G)**

287 Considering the highly conserved nature of the wild-type splice donor variant
288 in *DMD* (NC_000023.11:g.32454661C>G, represented as 'C' in Figure 3a-3b),
289 we generated transgenic mice with the mutant variant ('G') using the CRISPR-
290 Cas9 editing technique (Figure 3c). We examined cryptorchidism phenotypes
291 in F2 male mice using MRI at weeks 4 and 10. In the *DMD* transgenic mice,
292 we found undescended testicles that are different from the wild-type mice of
293 the same age (Figure 3d). The undescended testicles were located in the
294 inguinal region, suggesting the involvement of the *DMD* gene in the
295 development of cryptorchidism.

296 Discussion

297 In this study, we conducted rare variants screening for cryptorchidism in
298 humans. Among the known genes related to cryptorchidism, the mutation
299 burden and rigorous filtering of rare and predicted deleterious variants support
300 the roles of *USP9Y*, *KDM6A*, *BCORL1*, and *UBA1* in the pathogenicity of
301 cryptorchidism. *USP9Y* is one of the three genes within an azoospermia factor
302 (AZFa) region. Previous studies have revealed that *USP9Y* showed increased
303 transcript levels in patients suffering from cryptorchidism after a treatment with
304 the gonadotropin-releasing hormone agonist GnRHa³⁵. Exome sequencing
305 has revealed the role of *BCORL1* in spermatogenesis³⁶. *UBA1* has been
306 reported in patients with Spinal Muscular Atrophy 2 and cryptorchidism³⁷.
307 *KDM6A* is related to the Kabuki syndrome, which may involve hypospadias
308 and cryptorchidism in males³⁸. However, most of these studies were not
309 designed specifically for investigating cryptorchidism-associated genes and
310 variants, so our study expands the phenotypic spectrum of these gene defects.

311 More importantly, we identified four novel candidate cryptorchid genes (*DMD*,
312 *ARSH*, *MAGEA4*, and *SHROOM2*) with genome-wide significant burdens of
313 rare mutations with both disruptive and sequence-altering impacts. The gene
314 *MAGEA4* (melanoma antigen family A, 4) is commonly used as a marker for
315 human spermatogonia³⁹. Based on the immunohistochemistry of *MAGEA4*,
316 the number of spermatogonia was decreased in cryptorchid testes compared
317 to the normal testes⁴⁰. Although poorly characterized, the gene *SHROOM2*

318 was reported in patients with infertility⁴¹. Notably, the findings of the
319 pathogenic variants of *DMD* are particularly interesting, because of the
320 established role of *DMD* in producing the protein dystrophin critical for muscle
321 development⁴². Clinical studies have revealed a positive correlation (OR, 2.83)
322 between the urogenital malformation and muscular disorders, possibly due to
323 muscular defects in the cremaster muscle or other inguinal tissues⁴³. *DMD*
324 defects have been reported extensively in Duchenne/Becker muscular
325 dystrophy^{44 45}. Considering the dynamic process involving the muscular
326 traction of the gubernaculum during the normal testes descent⁴⁶, our
327 study suggests that muscular abnormalities may play a major role in
328 cryptorchidism.

329 As the maternal effect is higher than the paternal effect for cryptorchidism (for
330 example, the recurrence rate is higher in maternal half-brothers than in
331 paternal half-brothers), the possibility of maternal inheritance has long been
332 suspected^{9 47}. In this study, we revealed the genetic basis of maternal
333 inheritance of cryptorchidism by finding the dominant role of X-chromosomal
334 genes and their maternal origin. Indeed, based on the pedigree-based Sanger
335 sequencing, we revealed that some X-chromosomal variants with available
336 parental samples were inherited from maternal rather than paternal lineages.
337 This result is consistent with the expectation of both the X-hemizyosity effect
338 and the nature of male-specific disease. Because of X-hemizyosity in males,
339 X-chromosomal pathogenic variants invariably affect the males, while
340 commonly being masked by a normal allele in heterozygous females. In

341 addition, the causative variant for a male-specific trait would affect males
342 more heavily than females, except in case of a pleiotropic effect of the variant
343 on both sexes. Clinically, such hereditary pattern could be utilized to screen
344 those sex-related genetic disorders in male humans and to develop
345 subsequent prevention and therapeutic measurements.

346 Together, among the total of eight known and novel genes affecting multiple
347 unrelated patients of cryptorchidism, seven are X-chromosomal genes and
348 one is a Y gene. The candidate variants of X-chromosomal genes follow the
349 expectation of maternal inheritance rather than *de novo* mutation. Thus, our
350 study revealed a predominant role of sex chromosomal, and particularly the
351 X-chromosomal, gene defects, in causing male cryptorchidism.

352 **Conclusion**

353 We identified rare pathogenic variants of four known candidate genes (*USP9Y*,
354 *UBA1*, *BCORL1*, and *KDM6A*) and four novel candidate genes (*ARSH*, *DMD*,
355 *MAGEA4*, and *SHROOM2*) in patients suffering from cryptorchidism.

356 Considering the chromosomal distribution, seven out of eight genes are within
357 the X-chromosome, and *USP9Y* is located on the Y-chromosome. This
358 reveals a predominant role of X-chromosomal genes in cryptorchidism. The
359 maternal origin of these X-chromosomal variants reflects the strong effect of
360 X-hemizyosity on male-specific diseases. We successfully replicated

361 cryptorchidism phenotypes in transgenic mice. These mice harbor a splice
362 donor loss variant in *DMD* (NC_000023.11:g.32454661C>G), establishing a
363 viable mouse model for future research and therapy studies of this condition.

364 **Materials and methods**

365 **DNA samples, patient background, and whole-genome sequencing**

366 DNA was extracted from peripheral whole blood of 115 patients and 19
367 parental controls, using a local database of variants from 2136 unaffected
368 men for subsequent comparison. The patients were diagnosed by pediatric
369 specialists of the West China Hospital (WCH) and West China Second
370 University Hospital (WCSUH). The parents were carefully inquired about
371 family history and all fathers denied the existence of cryptorchidism in the
372 family history. All participating parents provided informed consent, and this
373 study was formally approved by the ethics committees of WCH (Registration
374 number: 2021389) and WCSUH (Registration number: 2021389). The WGS
375 (150 bp paired-end) data of an insert size of 350 bp were sequenced using
376 the DNBSEQ-T7 platform (MGI), according to the manufacturer's protocol
377 (Supplementary Table 1).

378 **Variants calling, genotyping, and annotation**

379 Based on the high-performance computing system, we locally conducted the
380 variant calling, genetic relationship, and population ancestry using the pipeline
381 described previously⁴⁸⁻⁵⁰. The rare variants were defined as alleles with
382 frequency lower than 0.01 in all geographic human populations of gnomAD

383 v3.1. Pathogenic variants were identified for known and novel genes
384 (Supplementary note).

385 **Validation of variants and genotypes using the Sanger sequencing**

386 Following the identification of candidate rare pathogenic variants, the Sanger
387 sequencing was conducted for all probands at first to remove false positive
388 variants due to errors in NGS sequencing or calling process. For the validated
389 variants in probands, we further conducted the Sanger sequencing for all
390 available parental samples, including samples from additional six trios in
391 which only probands had WGS data. The parental genotypes were further
392 used to evaluate the origin of variants.

393 **The C56BL/6J transgenic mouse modeling**

394 For the highly conserved variant, transgenic mouse was modeled using the
395 CRISPR-Cas9 editing technique. Briefly, the process was carried out in two
396 main stages: the in vitro stage and the in vivo stage. In the in vitro stage, the
397 process began with the design and construction of guide RNAs (gRNAs)
398 specific to the target DNA sequence around variant, followed by the design
399 and construction of the donor vector, which carried the desired genetic
400 modification. The in vivo stage involved microinjecting the designed gRNA
401 and donor vector into fertilized eggs, and then transplanting these embryos
402 into surrogate mothers. This led to the birth of the F0 generation mice, which
403 were subsequently screened to identify individuals with successful genetic
404 modifications. Positive F0 generation mice were then bred to produce the F1
405 generation, and these offspring were also screened to confirm the presence of

406 the genetic modification. The F2 mice were examined for phenotypes with
407 MRI (Time Medical Systems, Inc, USA).

408 **Statements & Declarations**

409 **Acknowledgements**

410 This study was supported by the fifth batch of technological innovation
411 research projects in Chengdu (2021-YF05 -01331-SN), the Postdoctoral
412 Research and Development Fund of West China Hospital of Sichuan
413 University (2020HXBH087), the Short-Term Expert Fund of West China
414 Hospital (139190032), Fund of Sichuan Provincial Department of Science and
415 Technology (2021YFS0244), and Fund of Sichuan Provincial Department of
416 Science and Technology (2021YFS0026). We also acknowledge the
417 computing support from the West China Biomedical Big Data Center and the
418 Med-X Center for Informatics of Sichuan University.

419 **Competing Interests**

420 The authors declare no competing financial interests.

421 **Author Contributions**

422 H.Y.X., C.Z.F., L.Z., and F.P.L. supervised this work. J.H.C., J.Z., K.Z., and
423 H.Z.D., designed the research. J.H.C., J.Z., and G.L.H analyzed data. J.H.C,
424 Y.Y.J, and J.Z. conducted lab work. G.L.H provided the candidate rare

425 variants screening in 2136 normal controls. J.H.C. drafted the manuscript and

426 all authors took part in revising and improving the manuscript.

427 **Data Availability**

428 The candidate variants data are listed in the supplementary tables. The

429 variants data could be available from the corresponding author on request.

430 **Ethics approval**

431 All authors declare that they have no Conflict of Interest. This study

432 conformed with the Helsinki Declaration of 1975 (as revised in 2008)

433 concerning Human and Animal Rights. All participating parents provided

434 informed consent, and this study was formally approved by the ethics

435 committees of WCH (Registration number: 2021389) and WCSUH

436 (Registration number: 2021389).

437 **Consent to participate**

438 Written informed consent was obtained from the parents.

439 **References**

440 1. Barthold JS, González R. The Epidemiology of Congenital Cryptorchidism, Testicular Ascent and

441 Orchiopexy. *Journal of Urology* 2003;170(6):2396-401. doi:

442 doi:10.1097/01.ju.0000095793.04232.d8

443 2. Agoulnik A, Ferguson L. Testicular Cancer and Cryptorchidism. 2013;4 doi:

444 10.3389/fendo.2013.00032

445 3. Kuiru-Hänninen T, Koskenniemi J, Dunkel L, et al. Postnatal Testicular Activity in Healthy Boys and

446 Boys With Cryptorchidism. *Frontiers in Endocrinology* 2019;10 doi:

447 10.3389/fendo.2019.00489

448 4. Raivio T, Toppari J, Kaleva M, et al. Serum Androgen Bioactivity in Cryptorchid and Noncryptorchid

449 Boys during the Postnatal Reproductive Hormone Surge. *The Journal of Clinical Endocrinology*

450 & *Metabolism* 2003;88(6):2597-99. doi: 10.1210/jc.2002-021676

- 451 5. Elamo HP, Virtanen HE, Toppari J. Genetics of cryptorchidism and testicular regression. *Best*
452 *Practice & Research Clinical Endocrinology & Metabolism* 2022;36(1):101619. doi:
453 <https://doi.org/10.1016/j.beem.2022.101619>
- 454 6. Chacko JK, Barthold JS. Genetic and environmental contributors to cryptorchidism. *Pediatr*
455 *Endocrinol Rev* 2009;6(4):476-80.
- 456 7. Elert A, Jahn K, Heidenreich A, et al. Population-based investigation of familial undescended testis
457 and its association with other urogenital anomalies. *Journal of Pediatric Urology*
458 2005;1(6):403-07. doi: 10.1016/j.jpuro.2005.04.005
- 459 8. Promm M, Schröder A, Neissner C, et al. Acquired cryptorchidism: More harm than thought?
460 *Journal of Pediatric Urology* 2016;12(4):236.e1-36.e6. doi: 10.1016/j.jpuro.2016.04.010
- 461 9. Schnack TH, Zdravkovic S, Myrup C, et al. Familial aggregation of cryptorchidism—a nationwide
462 cohort study. 2008;167(12):1453-57.
- 463 10. Barthold JS, Wang Y, Kolon TF, et al. Pathway analysis supports association of nonsyndromic
464 cryptorchidism with genetic loci linked to cytoskeleton-dependent functions. *Human*
465 *Reproduction* 2015;30(10):2439-51. doi: 10.1093/humrep/dev180
- 466 11. Bloom JS, Boocock J, Treusch S, et al. Rare variants contribute disproportionately to quantitative
467 trait variation in yeast. *eLife* 2019;8:e49212. doi: 10.7554/eLife.49212
- 468 12. Walter K, Min JL, Huang J, et al. The UK10K project identifies rare variants in health and disease.
469 *Nature* 2015;526(7571):82-90. doi: 10.1038/nature14962
- 470 13. Maher MC, Uricchio LH, Torgerson DG, et al. Population Genetics of Rare Variants and Complex
471 Diseases. *Human Heredity* 2012;74(3-4):118-28. doi: 10.1159/000346826
- 472 14. Halvorsen M, Huh R, Oskolkov N, et al. Increased burden of ultra-rare structural variants localizing
473 to boundaries of topologically associated domains in schizophrenia. *Nature Communications*
474 2020;11(1):1842. doi: 10.1038/s41467-020-15707-w
- 475 15. Kryukov GV, Pennacchio LA, Sunyaev SR. Most Rare Missense Alleles Are Deleterious in Humans:
476 Implications for Complex Disease and Association Studies. *The American Journal of Human*
477 *Genetics* 2007;80(4):727-39. doi: <https://doi.org/10.1086/513473>
- 478 16. Abrahams L, Savisaar R, Mordstein C, et al. Evidence in disease and non-disease contexts that
479 nonsense mutations cause altered splicing via motif disruption. *Nucleic Acids Research*
480 2021;49(17):9665-85. doi: 10.1093/nar/gkab750
- 481 17. Ganna A, Satterstrom FK, Zekavat SM, et al. Quantifying the Impact of Rare and Ultra-rare Coding
482 Variation across the Phenotypic Spectrum. *The American Journal of Human Genetics*
483 2018;102(6):1204-11. doi: 10.1016/j.ajhg.2018.05.002
- 484 18. Li J, Kong N, Han B, et al. Rare variants regulate expression of nearby individual genes in multiple
485 tissues. *PLOS Genetics* 2021;17(6):e1009596. doi: 10.1371/journal.pgen.1009596

- 486 19. Gorlov I, Gorlova O, Frazier M, et al. Evolutionary evidence of the effect of rare variants on disease
487 etiology. *Clinical Genetics* 2011;79(3):199-206. doi: <https://doi.org/10.1111/j.1399->
488 [0004.2010.01535.x](https://doi.org/10.1111/j.1399-0004.2010.01535.x)
- 489 20. Wang J, Lu Y, Yan X, et al. Identification of novel MITF mutations in Chinese families with
490 Waardenburg syndrome type II. *Molecular Genetics & Genomic Medicine* 2021;9(9):e1770.
491 doi: <https://doi.org/10.1002/mgg3.1770>
- 492 21. Bu F, Zhong M, Chen Q, et al. DVPred: a disease-specific prediction tool for variant pathogenicity
493 classification for hearing loss. *Hum Genet* 2022;141(3-4):401-11. doi: 10.1007/s00439-022-
494 02440-1 [published Online First: 20220219]
- 495 22. Cheng J, Zhou X, Lu Y, et al. Exome sequencing identifies a novel frameshift mutation of MYO6 as
496 the cause of autosomal dominant nonsyndromic hearing loss in a Chinese family. *Ann Hum*
497 *Genet* 2014;78(6):410-23. doi: 10.1111/ahg.12084 [published Online First: 20140917]
- 498 23. Sun Y, Cheng J, Lu Y, et al. Identification of two novel missense WFS1 mutations, H696Y and R703H,
499 in patients with non-syndromic low-frequency sensorineural hearing loss. *J Genet Genomics*
500 2011;38(2):71-6. doi: 10.1016/j.jcg.2011.01.001 [published Online First: 20110223]
- 501 24. Cheng J, Zhu Y, He S, et al. Functional mutation of SMAC/DIABLO, encoding a mitochondrial
502 proapoptotic protein, causes human progressive hearing loss DFNA64. *Am J Hum Genet*
503 2011;89(1):56-66. doi: 10.1016/j.ajhg.2011.05.027 [published Online First: 20110630]
- 504 25. Yuan Y, Huang D, Yu F, et al. A de novo GJB2 (connexin 26) mutation, R75W, in a Chinese pedigree
505 with hearing loss and palmoplantar keratoderma. *Am J Med Genet A* 2009;149a(4):689-92.
506 doi: 10.1002/ajmg.a.32461
- 507 26. Ayers K, Kumar R, Robevska G, et al. Familial bilateral cryptorchidism is caused by recessive
508 variants in RFXP2. *Journal of medical genetics* 2019;56(11):727-33.
- 509 27. Belkadi A, Bolze A, Itan Y, et al. Whole-genome sequencing is more powerful than whole-exome
510 sequencing for detecting exome variants. *Proceedings of the National Academy of Sciences*
511 2015;112(17):5473-78. doi: doi:10.1073/pnas.1418631112
- 512 28. Hiatt SM, Thompson ML, Prokop JW, et al. Deleterious Variation in BRSK2 Associates with a
513 Neurodevelopmental Disorder. *The American Journal of Human Genetics* 2019;104(4):701-08.
514 doi: 10.1016/j.ajhg.2019.02.002
- 515 29. McDougal WS, Wein AJ, Kavoussi LR, et al. Campbell-Walsh Urology 11th Edition Review E-Book:
516 Elsevier Health Sciences 2015.
- 517 30. Sun Y, Liu F, Fan C, et al. Characterizing sensitivity and coverage of clinical WGS as a diagnostic test
518 for genetic disorders. *BMC Medical Genomics* 2021;14(1):102. doi: 10.1186/s12920-021-
519 00948-5

- 520 31. Kishikawa T, Momozawa Y, Ozeki T, et al. Empirical evaluation of variant calling accuracy using
521 ultra-deep whole-genome sequencing data. *Scientific Reports* 2019;9(1):1784. doi:
522 10.1038/s41598-018-38346-0
- 523 32. Canese K, Weis S. PubMed: the bibliographic database. *The NCBI handbook* 2013;2(1)
- 524 33. McLaren W, Gil L, Hunt SE, et al. The ensembl variant effect predictor. *Genome biology*
525 2016;17(1):1-14.
- 526 34. Zhan X, Hu Y, Li B, et al. RVTESTS: an efficient and comprehensive tool for rare variant association
527 analysis using sequence data. *Bioinformatics* 2016;32(9):1423-26.
- 528 35. Gegenschatz-Schmid K, Verkauskas G, Stadler MB, et al. Genes located in Y-chromosomal regions
529 important for male fertility show altered transcript levels in cryptorchidism and respond to
530 curative hormone treatment. *Basic and Clinical Andrology* 2019;29(1):8. doi:
531 10.1186/s12610-019-0089-3
- 532 36. Lu C, Zhang Y, Qin Y, et al. Human X chromosome exome sequencing identifies BCORL1 as
533 contributor to spermatogenesis. *Journal of Medical Genetics* 2021;58(1):56-65. doi:
534 10.1136/jmedgenet-2019-106598
- 535 37. Öztürk Ö, Çavdarıtepe BE, Bağış H. X-Linked Spinal Muscular Atrophy 2 due to a Synonymous
536 Variant in the UBA1 Gene in a Family with Novel Findings from Turkey. *Molecular*
537 *Syndromology* 2022;13(3):246-53. doi: 10.1159/000519640
- 538 38. Armstrong L, Moneim AAE, Aleck K, et al. Further delineation of Kabuki syndrome in 48 well-
539 defined new individuals. *American Journal of Medical Genetics Part A* 2005;132A(3):265-72.
540 doi: <https://doi.org/10.1002/ajmg.a.30340>
- 541 39. He Z, Kokkinaki M, Jiang J, et al. Isolation, Characterization, and Culture of Human
542 Spermatogonia1. *Biology of Reproduction* 2010;82(2):363-72. doi:
543 10.1095/biolreprod.109.078550
- 544 40. Yang S, Ping P, Ma M, et al. Generation of Haploid Spermatids with Fertilization and Development
545 Capacity from Human Spermatogonial Stem Cells of Cryptorchid Patients. *Stem Cell Reports*
546 2014;3(4):663-75. doi: 10.1016/j.stemcr.2014.08.004
- 547 41. Fabian-Jessing BK, Vestergaard EM, Plomp AS, et al. Ocular albinism with infertility and late-onset
548 sensorineural hearing loss. 2018;176(7):1587-93. doi: <https://doi.org/10.1002/ajmg.a.38836>
- 549 42. Duan D, Goemans N, Takeda Si, et al. Duchenne muscular dystrophy. *Nature Reviews Disease*
550 *Primers* 2021;7(1):13. doi: 10.1038/s41572-021-00248-3
- 551 43. Diniz G, Barutcuoglu M, Unalp A, et al. Evaluation of the relationship between urogenital
552 abnormalities and neuromuscular disorders Evaluation of the relationship between
553 urogenital abnormalities and. 2008;13(1-2):19-24.
- 554 44. Moser H. Duchenne muscular dystrophy: pathogenetic aspects and genetic prevention. *Human*
555 *genetics* 1984;66(1):17-40.

- 556 45. Emery AE, Muntoni F, Quinlivan R. Duchenne muscular dystrophy: Oxford Monographs on Medical
557 G 2015.
- 558 46. Hutson JM, Hasthorpe S, Heyns CF. Anatomical and Functional Aspects of Testicular Descent and
559 Cryptorchidism*. *Endocrine Reviews* 1997;18(2):259-80. doi: 10.1210/edrv.18.2.0298
- 560 47. Jensen MS, Toft G, Thulstrup AM, et al. Cryptorchidism concordance in monozygotic and dizygotic
561 twin brothers, full brothers, and half-brothers. *Fertility and Sterility* 2010;93(1):124-29. doi:
562 10.1016/j.fertnstert.2008.09.041
- 563 48. Chen J, Zhang P, Chen H, et al. Whole-genome sequencing identifies rare missense variants of
564 WNT16 and ERVW-1 causing the systemic lupus erythematosus. *Genomics*
565 2022;114(3):110332. doi: <https://doi.org/10.1016/j.ygeno.2022.110332>
- 566 49. Oud MS, Houston BJ, Volozonoka L, et al. Exome sequencing reveals variants in known and novel
567 candidate genes for severe sperm motility disorders. *Human Reproduction* 2021;36(9):2597-
568 611. doi: 10.1093/humrep/deab099
- 569 50. Jia Y, Chen J, Zhong J, et al. Novel rare mutation in a conserved site of PTPRB causes human
570 hypoplastic left heart syndrome. *Clinical Genetics* 2023;103(1):79-86. doi:
571 <https://doi.org/10.1111/cge.14234>

572

573 Table 1. The candidate pathogenic variants of known genes. “B” and “U” in ID
574 column are “bilateral cryptorchidism” and “unilateral cryptorchidism”,
575 respectively. The “Pred” column shows the number of prediction methods
576 that support deleterious effects of the variants (see Supplementary Table 3
577 for specific methods). Note: USP9Y (underlined) is a Y chromosome gene,
578 while all other genes reside on the X chromosome.

ID	HVGS	Gene,Chr	Pred
U106	NC_000023.11:g.130028727G>A;NP_001171701.1:p.(G1391R)	<i>BCORL1</i>	6
U37	NC_000023.11:g.130028727G>A;NP_001171701.1:p.(G1391R)	<i>BCORL1</i>	6
U50	NC_000023.11:g.130028727G>A;NP_001171701.1:p.(G1391R)	<i>BCORL1</i>	6
U9	NC_000023.11:g.130028727G>A;NP_001171701.1:p.(G1391R)	<i>BCORL1</i>	6
U60	NC_000023.11:g.45069958A>C;NP_001278345.1:p.(K775T)	<i>KDM6A</i>	5
U58	NC_000023.11:g.45110152A>G;NP_001278344.1:p.(D1412G)	<i>KDM6A</i>	6
U51	NC_000023.11:g.47212835A>T;NP_003325.2:p.(Y873F)	<i>UBA1</i>	11
U60	NC_000023.11:g.47214843G>C;NP_695012.1:p.(V1031L)	<i>UBA1</i>	5
U49	NC_000024.10:g.12722148G>A;NP_004645.2:p.(E96K)	<u>USP9Y</u>	6
U50	NC_000024.10:g.12722148G>A;NP_004645.2:p.(E96K)	<u>USP9Y</u>	7
U109	NC_000024.10:g.12739592C>G;NP_004645.2:p.(S462C)	<u>USP9Y</u>	5
U73	NC_000024.10:g.12739592C>G;NP_004645.2:p.(S462C)	<u>USP9Y</u>	5

U13	NC_000024.10:g.12739592C>G;NP_004645.2:p.(S462C)	<u>USP9Y</u>	5
U71	NC_000024.10:g.12739592C>G;NP_004645.2:p.(S462C)	<u>USP9Y</u>	5

579

580 Table 2. The pathogenic variants in novel candidate genes. “B” and “U” in the
 581 ID column are “bilateral cryptorchidism” and “unilateral cryptorchidism”,
 582 respectively. The “Pred” column shows the number of prediction methods
 583 supporting the variants as deleterious (see Supplementary Table 4 for specific
 584 *in silico* prediction algorithms). Note: all genes are on the X chromosome.

ID	HGVSc	Gene	Pred
U27	NC_000023.11:g.3024049G>C;NP_001011719.1:p.(E310D)	ARSH	5
U64	NC_000023.11:g.3024093G>C;NP_001011719.1:p.(G325A)	ARSH	13
B122	NC_000023.11:g.3033050C>G;NP_001011719.1:p.(P452A)	ARSH	9
U127	NC_000023.11:g.3033050C>G;NP_001011719.1:p.(P452A)	ARSH	9
U28	NC_000023.11:g.3033050C>G;NP_001011719.1:p.(P452A)	ARSH	9
U42	NC_000023.11:g.31774145C>T; LRG_199p1:p.(E2453K)	DMD	3
U55	NC_000023.11:g.32342234G>A;NP_004000.1:p.(R1926C)	DMD	6
U114	NC_000023.11:g.32346044G>C;NP_000100.2:p.(Q1821E)	DMD	1
U58	NC_000023.11:g.32346044G>C;NP_000100.2:p.(Q1821E)	DMD	1
B130	NC_000023.11:g.32454661C>G (splice donor loss variant)	DMD	1
U70	NC_000023.11:g.32472199A>G;NP_000100.2:p.(Y964H)	DMD	5
U111	NC_000023.11:g.32573783C>T; NP_000100.2:p.(D548N)	DMD	7
U106	NC_000023.11:g.151924064G>A;NP_001011550.1:p.(A134T)	MAGEA4	2
U36	NC_000023.11:g.151924064G>A;NP_001011550.1:p.(A134T)	MAGEA4	2
U8	NC_000023.11:g.151924064G>A;NP_001011550.1:p.(A134T)	MAGEA4	2
U94	NC_000023.11:g.151924064G>A;NP_001011550.1:p.(A134T)	MAGEA4	2
U27	NC_000023.11:g.151924194A>T;NP_001373127.1:p.(Y177F)	MAGEA4	4
U98	NC_000023.11:g.9786618C>A;NP_001640.1:p.(R25S)	SHROOM2	2
U33	NC_000023.11:g.9894590G>A;NP_001640.1:p.(D228N)	SHROOM2	2
U2	NC_000023.11:g.9937394C>T;NP_001307593.1:p.(P118L)	SHROOM2	5
U55	NC_000023.11:g.9937537G>T;NP_001307593.1:p.(A166S)	SHROOM2	2
B79	NC_000023.11:g.9937537G>T;NP_001307593.1:p.(A166S)	SHROOM2	5
B81	NC_000023.11:g.3024049G>C;NP_001011719.1:p.(E310D)	SHROOM2	5

585

586 Table 3. The significance levels of burden tests for novel candidate genes
 587 with rare variants.

Gene	CMC	CMCFisherExact	CMCWald	Fp	Zeggini
ARSH	5.90E-20	1.19E-06	2.20E-05	4.12E-21	5.90E-20
DMD	2.01E-38	8.39E-15	3.54E-18	1.32E-52	2.01E-38

<i>MAGEA4</i>	3.11E-65	2.32E-22	7.75E-23	2.25E-18	1.48E-52
<i>SHROOM2</i>	5.41E-32	1.48E-11	6.67E-13	1.40E-46	5.41E-32

588

589

590

Figures legends

591 Figure 1. The Magnetic Resonance Imaging (MRI) and Sequencing Depth. (a-
592 e) The two magnetic resonance imaging (MRI) graphs for bilateral
593 cryptorchidism (case B130). (c-d) The two MRI graphs for unilateral
594 cryptorchidism (case U111). (e) The MRI for one control. The red arrows
595 show the location of the testes. (f) The WGS overall depths for the cases (red)
596 and control (green).

597 Figure 2. The Pedigree Information and the Chromatogram of the Sanger
598 Sequencing Results For Cases and Their Parents. (a) The pedigree
599 information for seven trios and four duos with WGS data. (b) The pedigree
600 information for six trios, with WGS data only for the cases. (c) The Sanger
601 sequencing chromatogram for candidate variants of known and novel genes.
602 “1/1”, “0/1”, and “0/0” are genotypes. U and B represent “unilateral” and
603 “bilateral”, respectively. “F” and “M” indicate “Father” and “Mother”,
604 respectively. “-F” and “-R” show the results of PCR sequencing from forward
605 primer and reverse primer, respectively.

606 Figure 3. Evolutionary Conservation of the Splice Donor Variant in *DMD*
607 (NC_000023.11:g.32454661C>G) and MRI of Transgenic and Normal Mice.
608 (a) Conservation of the *DMD* variant (NC_000023.11:g.32454661C>G)
609 according to the UCSC Vertebrate Alignment. (b) Conservation based on the
610 Amniote alignment from the Ensembl database. (c) Schematic representation
611 of a transgenic mouse with CRISPR-Cas9 editing. (d) Position of the testicles
612 in normal C57 mice compared to *DMD* transgenic mice, as determined by
613 MRI. Undescended testicles were observed in the *DMD* transgenic mice at
614 both 4 and 10 weeks, with both testicles located in the inguinal region.







615 Supplementary Figure 1. The Screening and Analyzing Process for Variants.
616 (a) The bioinformatics pipeline for variant calling, filtering, and genotyping with
617 WGS data. (b) The relationship network among all cases and their family
618 members. Thicker lines indicate closer genetic relationships. (c) The PCA for
619 population identity of newly sequenced individuals conducted by incorporating
620 major populations from the “1000 genomes” project, including African (AFR),
621 American (AMR), European (EUR), South Asian (SAS), and East Asian
622 (Chinese Dai in Xishuanagbanna, CDX; Han Chinese in Beijing, CHB; Han
623 Chinese South, CHS; Japanese in Tokyo, Japan, JPT; Kinh in Ho Chi Minh
624 City, Vietnam, KHV) populations.







625 Supplementary Figure 2. The evolutionary conservation of sites for known
626 genes across primate species, based on the Ensembl (v105) sequence
627 alignments of orthologous genes. The arrows show the locations of variants.


628 Supplementary Figure 3. The Sanger sequencing confirmation for known
629 genes (*UBA1*, *USP9Y*, *KDM6A*, and *BCORL1*) related to cryptorchidism.

630 Supplementary Figure 4. The evolutionary conservation of sites for novel
631 candidate genes across primate species, based on the Ensembl (v105)
632 sequence alignments of orthologous genes. The arrows show the loci with
633 gene names and variant information.

634 Supplementary Figure 5. The Sanger sequencing validation of four novel
635 candidate genes (*DMD*, *ARSH*, *MAGEA4*, and *SHROOM2*) related to
636 cryptorchidism (B130 was not tested due to insufficient amount of DNA).







b

NC_000023.11:g.32454661C>G

